Candel Therapeutics, Inc. (CADL) stock
CADLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$5.32−0.08 (-1.48%)
Close on Nov 18, 2026Market cap $407.08MP/E –Yield –
Candel Therapeutics price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Candel Therapeutics's price to sales ratio was 298.4× on Apr 28, 2023.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2023 | Apr 28, 2023 | 298.4× | −118.6 |
| 2022 | Dec 30, 2022 | 417.1× | – |
See a number that looks wrong?